Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OTC Markets OTCPK - Delayed Quote USD

Bavarian Nordic A/S (BVNRY)

Compare
7.31
-0.07
(-0.95%)
At close: April 2 at 3:58:54 PM EDT
Loading Chart for BVNRY
  • Previous Close 7.38
  • Open 7.13
  • Bid 7.26 x 40000
  • Ask 7.32 x 40000
  • Day's Range 7.13 - 7.31
  • 52 Week Range 7.13 - 14.60
  • Volume 645
  • Avg. Volume 9,977
  • Market Cap (intraday) 1.723B
  • Beta (5Y Monthly) 1.68
  • PE Ratio (TTM) 11.98
  • EPS (TTM) 0.61
  • Earnings Date May 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Mar 27, 2020
  • 1y Target Est --

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

www.bavarian-nordic.com

1,605

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BVNRY

View More

Performance Overview: BVNRY

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .

YTD Return

BVNRY
16.60%
OMX Copenhagen 25 Index (^OMXC25)
4.06%

1-Year Return

BVNRY
37.41%
OMX Copenhagen 25 Index (^OMXC25)
11.38%

3-Year Return

BVNRY
37.41%
OMX Copenhagen 25 Index (^OMXC25)
5.44%

5-Year Return

BVNRY
37.41%
OMX Copenhagen 25 Index (^OMXC25)
53.03%

Compare To: BVNRY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BVNRY

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    1.70B

  • Enterprise Value

    1.40B

  • Trailing P/E

    12.00

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.07

  • Price/Book (mrq)

    1.03

  • Enterprise Value/Revenue

    1.70

  • Enterprise Value/EBITDA

    5.79

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.28%

  • Return on Assets (ttm)

    4.60%

  • Return on Equity (ttm)

    9.09%

  • Revenue (ttm)

    5.72B

  • Net Income Avi to Common (ttm)

    987.98M

  • Diluted EPS (ttm)

    0.61

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.18B

  • Total Debt/Equity (mrq)

    1.39%

  • Levered Free Cash Flow (ttm)

    -421M

Research Analysis: BVNRY

View More

Company Insights: BVNRY

Research Reports: BVNRY

View More

People Also Watch